Production (Stage)
Oruka Therapeutics, Inc.
ORKA
$12.58
$0.393.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.74M | 12.58M | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 113.48M | 95.26M | -- | -- | -- |
| Operating Income | -113.48M | -95.26M | -- | -- | -- |
| Income Before Tax | -105.26M | -84.26M | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -105.26 | -84.26 | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -105.26M | -91.34M | -- | -- | -- |
| EBIT | -113.48M | -95.26M | -- | -- | -- |
| EBITDA | -91.95M | -66.88M | -- | -- | -- |
| EPS Basic | -50.09 | -64.87 | -- | -- | -- |
| Normalized Basic EPS | -31.78 | -31.46 | -- | -- | -- |
| EPS Diluted | -50.09 | -64.87 | -- | -- | -- |
| Normalized Diluted EPS | -31.78 | -31.46 | -- | -- | -- |
| Average Basic Shares Outstanding | 101.02M | 59.34M | -- | -- | -- |
| Average Diluted Shares Outstanding | 101.02M | 59.81M | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |